Company news

Lixte Biotechnology Holdings, Inc. news in 2025

Lixte Biotechnology Holdings, Inc.'s news releases, calls and decks from 2025, newest first.

View company

LIXTE and its Collaborators Expand Clear Cell Ovarian Cancer Trial

December 23, 2025

Lixte Biotechnology Holdings, Inc. Announces $4.3 Million Registered Direct Offering Priced at the Market Under Nasdaq Rules

December 18, 2025

LIXTE Biotechnology Acquires Liora Technologies' Proprietary Proton Therapy Platform for Cancer Treatment

November 26, 2025

LIXTE Biotechnology Acquires Liora Technologies’ Proprietary Proton Therapy Platform for Cancer Treatment

November 25, 2025

LIXTE Biotechnology Holdings to Present at the Spartan Capital Investor Conference 2025, November 3

October 29, 2025

LIXTE Biotechnology Holdings Highlights Q4 2025 Priorities, Including Ongoing Advancement of Lead Candidate LB-100, Strategic Oncology Business Development and Acquisition Plans

October 16, 2025

LIXTE Bio's Transformational Summer Marked by Leadership Updates, Scientific Progress, and Digital Treasury Strategy (NASDAQ: LIXT)

September 14, 2025

LIXTE Biotechnology Holdings Makes $2.6 Million Initial Purchase of Digital Currency to Diversify Treasury and for Potential Acquisitions

September 10, 2025

LIXTE Biotechnology Holdings Appoints Two New Board Members and New Chief Financial Officer

September 3, 2025

LIXTE Biotechnology Holdings Provides Corporate Update

August 18, 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with First Phase 1B/2 Trial Readout Expected in 2H 2025

August 14, 2025

24/7 Market News: LIXTE Biotech Advances Precision Oncology Pipeline with Multiple Phase 1B/2 Trial Readouts Expected in 2H 2025

August 14, 2025

LIXTE Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency

August 12, 2025

LIXTE Biotechnology Holdings Regains Compliance with Nasdaq’s Continued Listing Requirements

July 16, 2025

New Clinical Findings Published in Scientific Journal Nature Validate LIXTE’s Ongoing Ovarian and Colorectal Cancer Trials

July 9, 2025

Lixte Biotechnology Holdings, Inc. Announces the Closing of $1.5 Million Registered Direct Offering

July 8, 2025

Lixte Biotechnology Holdings, Inc. Announces the Closing of $5.0 Million Private Placement Priced at the Market

July 2, 2025

Lixte Biotechnology Holdings, Inc. Announces $5.0 Million Private Placement Priced at the Market

July 1, 2025

LIXTE Launches New Study to Determine if Certain Pre-Cancerous Cells Found in an Aging Population Can Be Eliminated by LB-100

March 31, 2025

LIXTE Biotechnology Provides Update On Progress with Proprietary Compound, LB-100, to Treat Ovarian and Colorectal Cancer

March 27, 2025

New Findings Show how LIXTE’s Lead Clinical Compound, LB-100, is Metabolized to its Active Form

March 10, 2025

LIXTE Adds Northwestern University’s Lurie Cancer Center as Second Site in Ongoing Clinical Trial for Ovarian Clear Cell Cancer

February 25, 2025

LIXTE Biotechnology Announces $1.05 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

February 10, 2025

LIXTE Biotechnology Submits Request for Withdrawal of Form S-1 Registration Statement

February 9, 2025